Work

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

Year: 2017

Type: article

Study design: Clinical Trial

Source: The Journal of Clinical Pharmacology

DOI: 10.1002/jcph.987

Authors: Michael J. Hanley, Neeraj Gupta, Karthik Venkatakrishnan, Alberto Bessudo, Sunil Sharma, Bert H. O'Neil, Bingxia Wang, Helgi van de Velde, John Nemunaitis

Institutions: Takeda Oncology (United States), California Cancer Associates for Research and Excellence, Huntsman Cancer Institute, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Mary Crowley Cancer Research Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Takeda Pharmaceutical Company, Takeda Oncology

OpenAlex ID: W2744449340

FWCI: 0.843

Cites: 30

Cited by: 5

Related to: 10